Medical/Pharmaceuticals
PharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALS
Highlights: * Monepantel displays a superior safety, tolerability to the leading FDA approved drug Relyvrio® * Preliminary efficacy data shows a 58% reduction in the rate of disease progression for Cohort 2 (High Dose) using the FDA primary efficacy endpoint, ALSFRS-R * Confirmation that m...
2024-02-28 20:47
1550
First product based on LTS Sorrel™ wearable drug delivery platform launched in the US
ANDERNACH, Germany, Feb. 28, 2024 /PRNewswire/ -- LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company, announced today that its customer Coherus BioSciences, Inc ("Coherus") has launched its UDENYCA® on-body injector (OBI) utilizing the LTS Sorrel™ wearable drug d...
2024-02-28 20:00
2247
Baird Medical Expands Presence in the United States
FRISCO, Texas, Feb. 28, 2024 /PRNewswire/ -- Baird Medical Devices, Inc. ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider inChina and the United States, today announced that it is accelerating its expansion inthe United States through ...
2024-02-28 18:00
1537
The promising results of a phase II clinical study for Akeso's Cadonilimab (PD-1/CTLA-4) combined standard treatment for first-line treatment of R/M cervical cancer has been published in Clinical Cancer Research
HONG KONG, Feb. 28, 2024 /PRNewswire/ -- Akeso (9926.HK) announced that the results of a phase II clinical trial for PD-1/CTLA-4 bispecific antibody（cadonilimab）combined with standard treatment (chemotherapy +/- bevacizumab) as first-line treatment for recurrent/metastatic cervical cancer had be...
2024-02-28 17:27
1875
The 20th International Congress on Luobing Theory Held in Shijiazhuang
SHIJIAZHUANG, China, Feb. 28, 2024 /PRNewswire/ -- On February 24, the 20th International Congress on Luobing Theory was held inShijiazhuang, which consisted of 1 main forum and 12 sub-forums. Approximately 20 academicians from both Chinese Academy of Sciences and Chinese Academy of Engineering, ...
2024-02-28 09:37
1479
Vieworks Unveils Cutting-Edge X-ray Imaging Solutions at ECR 2024
ANYANG, South Korea, Feb. 28, 2024 /PRNewswire/ -- Vieworks, a leading provider of medical and industrial X-ray imaging solutions, is gearing up to showcase its innovative lineup at the European Congress of Radiology (ECR) 2024, scheduled fromFebruary 28 to March 3 in Vienna, Austria. Vieworks wi...
2024-02-28 04:01
1594
BioCina and NovaCina Forge Strategic Alliance to Offer Biologics Developers Integrated Drug Substance and Drug Product Solutions
ADELAIDE, South Australia, and PERTH, Western Australia, Feb. 27, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish CDMO, announced a strategic partnership to provide in...
2024-02-28 02:30
1318
FDA Grants Fast Track Designation to 9MW2821
SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces that its self-developed novel ADC drug targeting Nectin-4 (R&D Code: 9MW2821) has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administ...
2024-02-27 22:00
1216
111 Announces Receipt of Withdrawal of Going Private Proposal
SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it has received a notice dated Feburary 27, 20...
2024-02-27 21:58
2706
Kakao Brain Unveils Labeler Project Exclusively for Medical Image preliminary report
* A Labeler project capable of diagnosing specific diseases from image readings written in natural language. * Capable of identifying a total of 13 diseases with high incidence rates and importance, including fractures, pleural lesions, and pneumothorax. * Recorded an accuracy of 90.39%, hig...
2024-02-27 21:00
1223
New Models of PENTAX Medical i20c Video Endoscope Series Obtain CE Marks
TOKYO, Feb. 27, 2024 /PRNewswire/ -- PENTAX Medical, a division of HOYA Group,
have obtained CE marks for new models of PENTAX Medical i20c Video Endoscope
Series - PENTAX Medical Video Colonoscope EC34-i20c, PENTAX Medical Video Upper
GI Scope EG27-i20c and R/L Knob Adaptor OE-B17.
2024-02-27 17:00
1482
Jenny Zheng joins Illumina as Senior Vice President and General Manager of Greater China
SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- On February 26, 2024, Illumina Inc. (NASDAQ: ILMN) a global leader in DNA sequencing and array-based technologies, announced thatJenny Zheng joins Illumina as Senior Vice President and General Manager ofGreater China, and a member of the global executive ma...
2024-02-27 16:09
1445
Amaris B. Clinic's Research Reveals Dynamic Skin Care Priorities Across Age Groups in Singapore
The data analysis concluded that the need for personalised solutions should exceed conventional beauty standards, prioritising holistic wellness and skin vitality. SINGAPORE, Feb. 27, 2024 /PRNewswire/ -- Amaris B Clinic, an established medical aesthetic, sculpting, and fitness clinic inSingapor...
2024-02-27 15:21
1505
Takeda Accelerates Access to its Dengue Vaccine Through 'Make in India' Manufacturing Partnership with Biological E.
* New strategic partnership will scale-up manufacturing capacity to support global supply of dengue vaccine and expands Takeda's footprint in vaccine manufacturing. * The strategic partnership will deliver potentially up to 50 million doses per year by 2030 to address global public health n...
2024-02-27 12:40
1536
Nona Biosciences Enters into Collaboration Agreement with Boostimmune in Antibody-Drug Conjugate Development
CAMBRIDGE, Mass., Feb. 26, 2024 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to cutting-edge technology innovations and providing a total solution from "Idea to IND" ("I to ITM"), announced today that it has entered into a collaboration agreement w...
2024-02-27 09:23
1585
Sengenics Corporation Announces Key Distributor in China
Sengenics Partners with Shanghai Universal Biotech Co., Ltd. (UniV) to Expand Reach of Immunoprofiling Products and Services inChina BOSTON, Feb. 27, 2024 /PRNewswire/ -- Sengenics Corporation LLC, a pioneer in the field of immunoproteomic biomarker discovery, proudly announces that it has enter...
2024-02-27 08:30
1766
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
SHANGHAI, China and SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) approved Kezar's investig...
2024-02-27 07:14
1749
Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics
MELBOURNE, Australia, Feb. 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based inA...
2024-02-27 05:55
8188
Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases
* Collaboration leverages Neomorph's leading molecular glue discovery platform and Novo Nordisk's extensive expertise in cardiometabolic and rare diseases * Total potential deal value of $1.46B across multiple targets SAN DIEGO, Feb. 27, 2024 /PRNewswire/ -- Neomorph, Inc. today announced it ...
2024-02-27 01:06
1695
BioCity Announces Enrollment Completion of the IgA Nephropathy (IgAN) Cohort in the Randomized, Placebo-controlled Phase II Clinical Trial of the ETA Receptor Antagonist SC0062
WUXI, China, Feb. 25, 2024 /PRNewswire/ -- BioCity Biopharma is pleased to announce the completion of enrollment of all 120 participants in the IgA nephropathy (IgAN) cohort in a randomized, double-blind, placebo-controlled Phase 2 clinical study of the novel, oral endothelin A (ETA)-receptor sel...
2024-02-26 22:38
1321
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8288
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7685